A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
Starting soon · Phase 2
Conditions studied: NSCLC (Advanced Non-small Cell Lung Cancer)
In brief
This study aims to evaluate the safety and efficacy of SCTB41 combined with docetaxel in patients with previously treated non-small cell lung cancer. The Phase II part of this study is an open-label, multicenter clinical trial.
Key facts
- Study ID
- NCT07609251
- Run by
- Sinocelltech Ltd.
- People needed
- 90
- Starts
- 2026-05-01
- Expected to finish
- 2029-07-01
- Last updated by the study team
- 2026-05-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Voluntarily sign the informed consent form (ICF);
- ECOG 0-1;
- Survival duration more than 3 months;
- Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) that is not amenable to complete surgical resection and cannot receive curative concurrent/sequential chemoradiotherapy;
- Without AGA: Have experienced disease progression during or after prior treatment with PD-(L)1 inhibitors and chemotherapy.With AGA: Must have received adequate targeted therapy; EGFR-positive patients must have received prior treatment with PD-(L)1/VEGF bispecific antibody and/or TROP-2 ADC;
- At least one measurable non-brain lesion according to RECIST v1.1;
- Adequate major organ function.
You may not qualify if…
- Histologically or cytologically confirmed presence of small cell carcinoma components;
- Prior treatment with docetaxel;
- Symptomatic central nervous system (CNS) metastases;
- Received the last dose of prior systemic anti-tumor therapy within 4 weeks before the first dose of study drug;
- Imaging findings at screening show tumor invasion into major blood vessels or surrounding vital organs, or the presence of a risk of esophagotracheal or esophagopleural fistula, which the investigator assesses as unsuitable for enrollment;
- History of hypertensive crisis or hypertensive encephalopathy; presence of uncontrolled hypertension despite medical therapy;
- Presence of any active autoimmune disease or history of autoimmune disease with anticipated risk of relapse;
- Bleeding tendency, high risk of bleeding, or coagulation disorders;
- Diagnosis of another malignancy;
- Severe infection, active infection, active tuberculosis, positive HIV antibody, active hepatitis B or hepatitis C, or known active syphilis prior to the first dose;
- Presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;
- History of non-infectious pneumonitis that required systemic corticosteroid therapy, or current presence of interstitial lung disease;
- Prior history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
- Known hypersensitivity to any component of the study drug; known hypersensitivity to taxanes; or history of severe hypersensitivity reaction to any other monoclonal antibody;
- Pregnant or breastfeeding women;
- Any other condition that the investigator considers inappropriate for enrollment.
Where it is running
- Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology — Wuhan, Hubei, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.